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Abstract
Innate and type 1 cell-mediated cytotoxic immunity function as important extracellular control mechanisms that maintain
cellular homeostasis. Interleukin-12 (IL12) is an important cytokine that links innate immunity with type 1 cell-mediated
cytotoxic immunity. We recently observed in vitro that tumor-derived Wnt-inducible signaling protein-1 (WISP1) exerts
paracrine action to suppress IL12 signaling. The objective of this retrospective study was three fold: 1) to determine whether
a gene signature associated with type 1 cell-mediated cytotoxic immunity was correlated with overall survival, 2) to
determine whether WISP1 expression is increased in invasive breast cancer, and 3) to determine whether a gene signature
consistent with inhibition of IL12 signaling correlates with WISP1 expression. Clinical information and mRNA expression for
genes associated with anti-tumor immunity were obtained from the invasive breast cancer arm of the Cancer Genome Atlas
study. Patient cohorts were identified using hierarchical clustering. The immune signatures associated with the patient
cohorts were interpreted using model-based inference of immune polarization. Reverse phase protein array, tissue
microarray, and quantitative flow cytometry in breast cancer cell lines were used to validate observed differences in gene
expression. We found that type 1 cell-mediated cytotoxic immunity was correlated with increased survival in patients with
invasive breast cancer, especially in patients with invasive triple negative breast cancer. Oncogenic transformation in
invasive breast cancer was associated with an increase in WISP1. The gene expression signature in invasive breast cancer
was consistent with WISP1 as a paracrine inhibitor of type 1 cell-mediated immunity through inhibiting IL12 signaling and
promoting type 2 immunity. Moreover, model-based inference helped identify appropriate immune signatures that can be
used as design constraints in genetically engineering better pre-clinical models of breast cancer.
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Introduction
The discovery of molecular targeted therapies revolutionized
the treatment of breast cancer. Tamoxifen, a small molecule
inhibitor of the estrogen receptor, was the first drug to inhibit the
growth of breast cancer cells that depend on female sex hormones.
More recently, trastuzumab was developed to inhibit the growth of
breast cancer cells that overexpress HER2, an oncogenic member
of the epidermal growth factor family of receptors [1]. Based upon
their demonstrated clinical impact, a pre-operative biopsy sample
is used to guide treatment based upon expression of the hormone
receptors for estrogen (ER) and progesterone (PR) and the
epidermal growth factor receptor HER2 [2]. While these
molecular targeted therapies have improved survival, de novo
and acquired resistance to these therapies present challenges for
achieving a durable clinical response [3,4].
The difficulties in achieving a durable clinical response using
molecular targeted therapies have sparked a renewed interest in
viewing cancer from an evolutionary perspective [5–7]. Thinking
about cancer from an evolutionary perspective involves three key
concepts. First, tumors are comprised of a heterogenous population
of cells. While non-genetic sources of heterogeneity have been
recognized for several decades [8], recent studies of breast cancer
using next generation sequencing have revealed the genetic
heterogeneity associated with oncogenesis [9–14]. Second, the
different cell types contained within the tumor microenvironment -
stromal cells, malignant clones, and cells of the immune system -
and their collective interactions comprise a dynamic system.
Dynamic systems typically have control mechanism that aim to
maintain the system in a desirable state, such as tissue homeostasis,
in the presence of external perturbations [15]. Identifying the
control architecture in biological systems remains a central
challenge. Third, cells of the population impinge upon a selective
fitness landscape that determines their fate. The selective landscape
is composed of intracellular and extracellular adaptive control
mechanisms that regulate tissue homeostasis. Many intracellular
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control mechanisms are well studied and form the foundation of the
hallmarks of cancer [16]. Innate and adaptive immunity function as
extracellular control mechanisms that regulate cellular homeostasis
[17] and, in contrast, are not well understood [5].
Cytokines coordinate innate and adaptive immunity and defects
in their action have pathogenic implications. For instance,
Interleukin-12 (IL12) is a cytokine that is produced by innate
immune cells and acts upon Natural Killer cells, CD8+ Cytotoxic
T cells, and CD4+ T helper cells to initiate a type 1 cell-mediated
adaptive immune response [18]. Genetic mutations in IL12p40
and one component of the IL12 receptor, IL12Rb1, have been
observed in patients with recurrent mycobacterial disease,
suggestive of insufficient type 1 cell-mediated immunity [19,20].
Genetic deletion of other component of the IL12 receptor,
IL12Rb2, increases susceptibility to spontaneous autoimmunity,
B-cell malignancies, and lung carcinomas [21]. Originally called
Natural Killer (NK) Cell Stimulating Factor, IL12 also enhances
the ability of NK and CD8+ Cytotoxic T cells to lyse target cells, a
mechanism exploited for tumor immunotherapy. For example,
IL12 was used as an adjuvant to promote NK-cell mediated killing
of HER2-positive breast cancer cells in patients treated with
trastuzumab [22]. As an adjuvant for tumor immunotherapy,
toxicity restricts the systemic delivery of IL12 [23]. However, local
delivery of IL12 to the tumor microenvironment promotes tumor
regression in the B16 melanoma model [24] and in the EL4
thymoma model [25]. Given that genetic defects in IL12 signaling
increase cancer incidence and enhanced local delivery of IL12
promotes tumor regression, we recently asked whether malignant
cells alter the selective fitness landscape by locally inhibiting the
response of immune cells to IL12. Using the B16 model for
melanoma, we identified that tumor-derived Wnt-inducible
signaling protein 1 (WISP1), a beta-catenin responsive oncogene
[26], exerts paracrine action on immune cells by inhibiting their
functional response to IL12 [27]. The objective of this retrospec-
tive study of invasive breast cancer was three-fold: 1) to determine
whether the gene signature associated with type 1 cell-mediated
cytotoxic immunity was correlated with overall survival, 2) to
determine whether WISP1 expression is increased in invasive
breast cancer, and 3) to determine whether a pattern of gene
expression consistent with inhibition of IL12 signaling axis
correlates with WISP1 expression.
Results
Type 1 cell-mediated immunity correlates with improved
survival in patients with invasive triple negative breast
cancer
In this retrospective cohort study, our first objective was to
determine whether there were distinct cohorts within the invasive
breast cancer arm of the TCGA study that can be defined based
upon type 1 cell-mediated immune response. Samples included in
the analysis were limited to those derived from patients diagnosed
with variants of invasive breast cancer (n = 520) and to those
obtained from normal breast tissue (n = 61) (see Dataset S1). As
listed in Table 1, normalized expression values were obtained for
genes that are associated with T cells, macrophages, and Natural
Killer cells and the functional roles that these cells play in cell-
mediated immunity. As macrophages and T cells can enhance or
inhibit cell-mediated immunity depending on polarization bias,
genes associated with alternative polarization states were also
included. Specifically, macrophages within the tumor microenvi-
ronment are thought to either promote (M1) or inhibit (M2)
cytotoxic cell-mediated immunity [28,29]. Similarly, effector T
cells alter their functional role in coordinating adaptive immunity
depending on the cytokines secreted by and the transcription
factors expressed by different subsets, which include type 1, type 2,
type 17, or T regulatory subsets [30,31]. We also included genes
associated with the IL12 cytokine family, as IL12 links innate to
adaptive immunity and other members of this cytokine family
have competing effects on immune bias (e.g., [32]).
Based upon immune-related gene expression, tissue samples
hierarchically clustered into two main groups (Figure 1 and Figure
S1). While more patients were associated with Group 1 (n= 370
versus n= 150), the two groups had similar patient population
characteristics with no difference between age, tumor stage,
menopause status, or lymph node status (Table 2). Based on either
molecular pathology or PAM50 intrinsic subtypes [33], the
molecular characteristics of tumors associated with these two
groups were significantly different (p{valuev1|10{4 - Table 2).
Triple negative (TN) breast cancer samples were significantly
enriched in group 2 with an odds ratio of 3.48 versus 0.38 for group
1. As expected, samples positive for either estrogen receptor (ER) or
progesterone receptor (PR) and negative for HER2 were enriched
in group 1. Given that molecular subtyping guides therapy selection,
6-year overall survival was estimated using Kaplan-Meiers curves
for group 1 versus group 2 cohorts stratified by adjuvant treatment,
if known, and by molecular pathology (Figure 2). Patients with TN
breast cancer that clustered with group 2 exhibited an increase in
overall 6-year survival compared with patients with TN breast
cancer that clustered with group 1 (p{valuev0:03 with hazard
ratio = 0.191 (95% C.I. 0.037–0.995)). While the number of events
is low for the TN breast cancer group, the overall trend in survival
was also observed at earlier time points (1-year survival
p{valuev0:032 with hazard ratiov0:01; 3-year survival p-
value= 0.126 with hazard ratio= 0.28; and 5-year survival p-
value= 0.054 with hazard ratio = 0.22). Patients with HER2+
breast cancer also exhibited a similar trend, but the difference in
overall survival did not reach a similar level of significance. In
contrast, no difference in 6-year survival was observed between the
group 1 and group 2 cohorts treated using adjuvant hormone
therapy, if known, or were positive for either ER or PR.
Author Summary
Effective anti-tumor immunity is proportional to the
number and to the cytotoxic activity of immune cells that
enter the tumor microenvironment. Recent advances in
cancer immunotherapy stem from increasing the number
of tumor-infiltrating immune cells by inhibiting immune
checkpoints or adoptive T cell therapy. Here, we used
computational methods to identify potential mechanisms
present within the tumor microenvironment that limit the
efficacy of anti-tumor immunity. Specifically, we found that
oncogenic transformation is associated with the induction
of tumor-derived biochemical cues, namely Wnt-inducible
signaling protein-1, that locally suppress anti-tumor
immunity. Moreover, we used model-based inference to
demonstrate that a gene signature consistent with
effective type 1 cell-mediated cytotoxic immunity is a
predictor of overall survival independent of molecular
pathology. Interestingly, patients with triple negative
breast cancer were more enriched in the cohort associated
with type 1 cell-mediated immunity. As this immune gene
signature is not present in current genetically engineered
mouse models of breast cancer, the results help identify
design constraints for engineering better pre-clinical
models of breast cancer. Demonstrating efficacy in pre-
clinical animal models is a pre-requisite for bringing
improved cancer immunotherapies into the clinic.
WISP1 Inversely Correlates with Type 1 Immunity
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Effective anti-tumor immunity depends on the product of the
number of immune cells present within the tumor microenviron-
ment and the efficacy of the immune cells present to elicit cell-
mediated cytotoxic immunity. To infer mechanistic differences in
anti-tumor immunity between the patient cohorts, we estimated
the magnitude and the quality of anti-tumor immunity from the
gene expression measurements. The relative magnitude of
immune cell infiltration was inferred from the average expression
values for genes associated with NK cells, T cells and macrophages
(Table 1). Compared to samples derived from normal tissues, the
group 1 cohort exhibited a gene expression signature associated
with reduced NK cell, T cell, and macrophage recruitment
(Figure 3A). In contrast to group 1, the immune cell signature in
the group 2 cohort suggested an increase in NK cell, T cell, and
macrophage recruitment relative to normal breast tissue. As
immune cell polarization influences the efficacy of anti-tumor
immunity, we used model-based inference to determine the
polarization signature. In normal breast tissue, T helper cells
were primarily polarized towards Th2 (p{valuev0:001) and
macrophages were polarized towards a M2 phenotype (Figure 3B,
p{valuev0:001). In invasive breast cancer, group 1 cohort
exhibited a mixed Th2 and Th17 immune bias and a strong Th1
bias was associated with group 2 samples (p{valuev0:001).
Consistent with the Th1 bias in group 2 samples, the genes
associated with a type 1 cell-mediated immune response were also
consistently expressed at higher levels in the group 2 cohort
compared to group 1 and normal tissue samples. Compared to the
null hypothesis for immune cell polarization, the macrophage
polarization bias in the group 1 cohort could not be distinguished
from a pattern of random gene expression and samples from the
group 2 cohort exhibited a strong M1 bias (p{valuev0:001).
Collectively, the genes associated with type 1 cell-mediated
immunity can be used to identify cohorts within invasive breast
cancer that correlate with improved 6-year survival, specifically in
patients with TN invasive breast cancer.
Increased WISP1 associates with oncogenic
transformation in invasive breast cancer
Principal component analysis (PCA) was used to gain insight
into the molecular differences between cohorts identified using
hierarchical clustering. As the samples from normal tissues
clustered predominantly with group 1, the group 1 cohort was
subdivided into three subsets (Figure S2A) with normal tissue
samples clustering into group 1a. Of the total variation contained
within the gene expression data, the first four principal compo-
nents (PCs) captured 54% of the variance (Figure S2B).
Differences among the clustered cohorts were observed for the
first four PCs while no significant differences among groups were
observed for the rest of the PCs (Figure S2C). Based upon the
loading coefficients for individual genes, the magnitude of PC1
corresponded to the extent of T cell-mediated (increases with CD2,
CD247, CD3G, CD3D, CD8A, and CD28 expression) type 1
cytotoxic immunity (increases with FASLG, IFNG, GZMB, TBX21,
IL12RB2, EOMES, PRF1, B2M and decreases with GATA3
expression) and PC2 captured a correlation between WISP1 and
the T cell lineage-defining transcription factors GATA3 and
PPARG. As described in the supplemental Text S1, a similar gene
expression signature was observed in the gene expression results
reported by Gluck et al. (GSE22358 [34]). PC projections of the
patient samples suggest that the extent of T cell-mediated
cytotoxic immunity within invasive breast cancer is a continuous
property, with TN breast cancer more prevalent at higher values
for PC1 and HER2+ breast cancer more prevalent at lower values
for PC1 (Figure S2C). Yet, the hierarchical clustering subdivided
Table 1. Genes associated with type 1 cell-mediated immunity.
Functional Annotation Genes Refs
CD4/CD8 T cell surface molecules CD247 CD3D CD3E CD3G ITGAL ITGB2 ICAM1 CD2 CD28 THY1 PTPRC [74]
T helper cell polarization
Th1 CD4 IFNG IL10 FASLG EOMES TBX21 [31]
Th2 CD4 IL4 IL5 IL6 IL10 GATA3 PPARG [31]
Th17 CD4 IL17A IL17F RORA RORC [31]
iTreg CD4 TGFB1 IL10 IL12A EBI3 RORC FOXP3 TBX21 CCR6 MYB [31]
IL12 and Stat4 Dependent Signaling
Pathways in Th1 Development
CD247 CD3D CD3E CD3G JAK2 CCR5 CXCR3 ETV5 IFNG IL12RB1 IL12RB2 IL12A IL12B
IL18 IL18R1 JUN MAPK14 MAPK8 MAP2K6 STAT4 TYK2
[74]
CTL mediated immune response
against target cells
CD247 CD3D CD3E CD3G CD8A FAS FASLG B2M GZMB ITGAL ITGB2 ICAM1 HLA-A PRF1 HLA-B
HLA-C
[74]
Natural Killer Cells KLRC1 KLRC2 KLRC3 KLRD1 –
Natural Killer Cell mediated cytotoxicity IFNA1 IFNA2 IFNG CD247 FAS FASLG GZMB ICAM1 KLRC1 KLRC2 KLRC3 KLRD1 PRF1 ITGAL ITGB2 [75]
NO2-dependent IL12 pathway in NK cells CD247 CD2 CD4 JAK2 CCR5 CXCR3 IFNG IL12RB1 IL12RB2 IL12A IL12B NOS2 STAT4 TYK2 [74]
Macrophages CD14 MRC1 CPM ITGAM NOS2 HLA.DRA HLA.DMA HLA.DOA HLA.DPA1 HLA.DQA1 HLA.DQA2 ––
Tumor Associated Macrophages
M1 IDO1 IL23A IL12B CCL17 IL1B [29]
M2 ARG1 TIMP2 LYVE1 KLF4 CD163 STAB1 [29]
IL12 Family of Cytokines IL12A IL12B IL23A EBI3 –
Additional Immunosuppressive
Mechanisms
CD274 PDCD1; CTNNB1 WISP1; HMGB1; HIF1A; BTLA; HAVCR2 (TIM-3); LAG3; TGFB1; MICA
MICB; VTCN1 (B7-H4)
(see Figure S5)
Cell Proliferation MKI67 –
doi:10.1371/journal.pcbi.1003409.t001
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this continuous property into two discrete cohorts. In contrast to
PC1, PC2 separated samples derived from invasive breast cancer
from normal breast tissue and, based upon the loading coefficients
for PC2, suggests that an increase in WISP1 expression correlates
with oncogenic transformation (Figure 3C - p{valuev1|
10{15). The average intensity of WISP1 antibody staining in an
independent tissue microarray that contained samples from
normal (n = 3) and breast carcinoma tissue (n = 9) were used to
validate that an increase in WISP1 correlates with oncogenic
transformation (Figure 4, panels A–C). The tissue microarrays
were consistent with the gene expression data such that WISP1
was increased in invasive breast cancer compared to normal breast
tissue (p{valuev0:001).
An increase in WISP1 correlates with a shift in immune
bias from Type 1 towards Type 2 immunity
T cell polarization is driven by competition among lineage-
defining transcription factors that are induced by the exogenous
action of polarizing cytokines [30]. By inducing T-bet, Interleu-
kin-12 (IL12) acts, in part, upon CD4+ T helper cells to organize
an effective type 1 cell-mediated immune response [18]. As a
potential inhibitor of a type 1 cell-mediated immune response, in
vitro co-culture assays identified WISP1 as a paracrine regulator
of immune cells by inhibiting response to IL12 [27]. Here, we
found that the loading coefficients associated with PC2 suggest
that the variation in WISP1 was also associated with two T cell
lineage-defining transcription factors: GATA3 and PPARG.
Specifically, WISP1 expression was correlated with GATA3
expression (Figure 3C - p{valuev1|10{9) and exhibited a
negative correlation with PPARG expression (see Figure S4A -
p{valuev1|10{15). The functional connection between
WISP1 and immune polarization is strengthened by the
observations that GATA3 expression also correlates with GATA3
protein abundance (Figure 4D - p{valuev1|10{15) and that
GATA3 expression does not correlate with changes in genome
copy numbers of GATA3 (Figure S4B - p{value~1). In addition,
Figure 1. Expression patterns of genes associated with cell-mediated immunity clustered into two main groups. mRNA expression
obtained from normal breast and invasive breast carcinoma tissue samples (columns) acquired as part of the Cancer Genome Atlas study [14] were
hierarchically clustered into two groups based upon the log2 median-normalized expression ratio for genes (rows) related to cell-mediated cytotoxic
immunity and tumor immunosuppression, as listed in Table 1. Tissue samples were characterized by morphology (i.e., normal, ductal, lobular, or
other) and molecular histology (i.e., expression of the estrogen receptor (ER+), progesterone receptor (PR+), or HER2 (HER2+)), as highlighted by the
blue bars on top. Gene expression is shown as a row-normalized heatmap. Red denotes under-expressed and violet denotes over-expressed relative
to the population mean. Dendrogram indicates the degree of similarity among genes (rows) or samples (columns) using the Ward’s minimum
distance method in R.
doi:10.1371/journal.pcbi.1003409.g001
Table 2. Characteristics of the patient population stratified by group membership.
Category Group 1 Group 2
Tumor
Stage` Group 1 Group 2 LN Status` Group 1 Group 2
Count 370 150 O 1 0 N0 89 49
Age (years){ 58.2 57.3 I 32 10 N0(i2) 65 32
95% CI 34–82 35–83 IA 28 13 N0(i+) 13 3
IB 5 1 N1 44 15
Molecular Pathology* IIA 117 65 N1a 60 18
ER+/PR+ 300 75 IIB 83 26 N1b 16 2
HER2+ 48 27 IIIA 59 17 N1c 1 1
TN 26 60 IIIB 12 3 N1mi 11 1
Odds Ratio* 0.38 3.48 IIIC 11 8 N2 21 11
95% CI 0.23–0.61 2.26–5.37 IV 11 3 N2a 20 9
X 11 4 N2b 0 0
PAM50 Intrinsic Subtypes* N3 9 1
Basal 30 65 N3a 12 6
HER2-like 30 27 N3b 0 0
Luminal A 203 24 N3c 0 1
Luminal B 99 27 NX 9 1
Normal-like 4 4
Menopausal status`
Pre 78 34
Peri 14 3
Post 180 73
Unknown 98 40
Statistical significance between group summary statistics was estimated using a two-sided unmatched Student’s t test ({ indicates p-value = 0.48). A Fisher’s Exact test
was used to test whether categorical data for group is different than population (` indicates p-value greater than 0.5, * indicates p-value less than 1|10{4). Age
summarized as mean and range that encloses 95% of the population. Odds ratio calculated based upon diagnosis of TN breast cancer within each cohort group.
LN= Lymph node.
doi:10.1371/journal.pcbi.1003409.t002
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GATA3 expression exhibited a negative correlation with IL12
receptor b 2 (Figure S4C - p{valuev1|10{15). Compared to
other putative immunosuppressive mechanisms present in the
tumor microenvironment, the WISP1-GATA3 signature was the
only mechanism that was higher in the group 1 cohort relative to
the group 2 cohort (see Figure S5).
Peroxisome proliferator-activated receptor c (PPARG) is a
ligand-activated transcription factor that plays an important role in
regulating immunity and oncogenesis [35]. For instance, Th2
polarization is associated, in part, with increases in GATA3, IL6,
and PPARG gene expression [31]. In contrast, Chung et al. report
that PPARG can form an inhibitory complex with nuclear factor
of activated T cells (NF-AT) that inhibits the transcription of IL4
in T helper cells [36]. In a mouse model of atopic asthma,
pharmacologic activation of PPARG reduces the canonical Th2
cytokines IL4 and IL13 and GATA3 protein in lung extracts [37].
Collectively, these results suggest that the gene set - CD4, IL4, IL5,
IL10, and GATA3 - is a better signature for a type 2 bias of T
helper cells as an increase in PPARG expression may sensitize Th2
effector cells to negative regulation by PPARG ligands and that
GATA3 and PPARG may be regulated independently. Using this
revised Th2 cell gene signature, the group 1 cohort is associated
with an increase in type 2 bias relative to the group 2 cohort and
normal breast tissue (Figure S6 - p{valuev0:001). The group 2
cohort exhibited a strong type 1 bias while a Th17 bias was
observed in samples from normal breast tissue. An expression
signature consistent with inducible T regulatory cells was not
observed in any of the cohorts (p{valuev0:001). Using a Cox
proportional hazards regression model, we also found that
polarization towards a T helper type 1 phenotype was a predictor
of survival independent of the molecular pathology (see Table S1).
Using bootstrap resampling of the genes listed in Table 1, the
model-based inference of type 1 polarization is a better predictor
of improved survival than 95% (i.e., p{valuev0:05) of the
random immune signatures for the 1 Yr, 3 Yr, and 6 Yr outcomes
and than 93% of the random signatures for 5 Yr outcome (see
Figure S7).
Alterations in IL12 receptor expression and MHC class I
abundance between groups are retained in
representative breast cancer cell lines
In addition to secreting WISP1, B16 model for melanoma also
overexpresses one component of the IL12 receptor, IL12Rb2,
that, in vitro, creates a local cytokine sink for IL12 [27]. We
have also found that STAT4 is phosphorylated irreversibly,
creating a short term memory to IL12 signaling that is limited
by cell proliferation [38]. Local delivery of IL12 to the tumor
microenvironment promotes tumor regression in the B16
melanoma model [24] and in the EL4 thymoma model [25].
Collectively, these studies imply that signaling by endogenous
IL12 within the tumor microenvironment helps to maintain T
cell polarization when cognate tumor antigens induce T cell
proliferation [39] and that manipulating this extracellular
control mechanism may impart a survival advantage to the
collective tumor population. Finally, we wanted to determine
whether IL12 receptor b2 was increased relative to IL12
receptor b1 in samples derived from tumors with active type 1
cell-mediated immune response. In invasive breast cancer, the
ratio of IL12RB2 to IL12RB1 expression was increased in the
group 2 cohort relative to the group 1 cohort (Figure 3D -
p{valuev1|10{15). As we had previously observed an
imbalance in copy numbers of the components of the IL12
receptor in malignant melanocytes, we measured IL12 receptor
b1 and IL12 receptor b2 copy numbers in the 184A1, BT474,
SKBR3, and MDA-MB-231 cell lines by flow cytometry
(Figure 5, panels A–B). While the copy numbers in these cell
lines were lower than what we had observed in the B16F0 and
B16F10 cell lines, the ratio of IL12 receptor b2 to IL12 receptor
b1 was increased in the triple-negative breast cancer model,
MDA-MB-231, relative to the other three cell lines (see
Figure 5C - p{valuev0:05).
We also observed that abundance of major histocompatibility
complex (MHC) class I molecules varied among these cell lines in
a pattern consistent with differences in type 1 cell-mediated
immunity (Figure 5D). Specificity in directing T cell-mediated
cytotoxic immunity depends on the presentation of peptides bound
to MHC class I molecules. A reduction in MHC class I expression
may reduce the efficacy of type 1 cell-mediated immunity in
controlling tumor growth. Given that the gene expression
signature associated with type 1 cell-mediated immunity varied
among the invasive breast cancer samples, we ascertained whether
there were any basal differences in copy numbers of MHC class
I among cell lines derived from the different cohorts. The
BT474 and SKBR3 cell lines are cell models of HER2+ breast
Figure 2. Triple negative breast cancer patients with enhanced
type-1 cell-mediated immunity exhibit an improved 6-year
survival. Adjuvant treatment of breast cancer is stratified based upon
the molecular histology, as summarized by a Venn diagram for this
cohort (A). While treatments were documented for 224 of the 520
patients in the cohort, the distribution of known adjuvant therapies are
indicated by the color circles (Hormone therapy - blue circle,
chemotherapy - green circle, and Herceptin immunotherapy - red
circle). Kaplan-Meier survival curves were obtained for invasive breast
cancer patients that were stratified by group membership (group 1 -
blue curves, group 2 - red curves) within a common adjuvant treatment
group. The treatment groups included triple negative breast cancer (B),
patients treated with adjuvant Herceptin plus HER2+ patients with
unknown treatment (C), and patients treated with adjuvant hormone
therapy plus other HER2- patients (D). Dotted lines indicate 95%
confidence bounds. The number of patients at risk as a function of time
are shown below the x-axis for each Kaplan-Meier curve. A p-value of
less than 0.05 was considered statistically significant.
doi:10.1371/journal.pcbi.1003409.g002
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cancer, a subset that exhibited a gene expression signature
associated with a low type 1 cell-mediated response. The 184A1
cell line is a cell model of normal breast tissue, which had an
intermediate type 1 cell-mediated response signature. The
MDA-MB-231 cell line is a cell model of triple negative breast
cancer, which exhibited a high type 1 cell-mediated response
signature. Copy numbers of MHC class I molecules were
assayed by flow cytometry (Figure 5D). Collectively, the copy
numbers of MHC class I molecules varied among the cell lines:
184A1 expressed 307K copies while BT474 and SKBR3
expressed lower copies (16K and 10K, respectively) and MDA-
MB-231 expressed higher copies (916K). The lower copies in the
BT474 and SKBR3 cell lines is consistent with previous studies
that report that over-expression of HER2/Neu reduces MHC
class I expression [40,41]. In summary, basal differences in
MHC class I and IL12 receptor copy numbers among the
184A1, BT474, SKBR3, and MDA-MB-231 cells lines are
consistent with a model of invasive breast cancer where the
molecular subtypes are distinguished by differences in type 1
cell-mediated immunity.
Existing genetically engineered mouse models for
spontaneous breast cancer do not reproduce immune
cell gene signature observed in TCGA data
Modeling breast cancer in mice inevitably involves some degree
of abstraction - one must determine key elements associated with
the human disease and select model systems that incorporate those
elements. Historically, transplantable models for cancer, like the
B16 melanoma and 4T1 breast cancer models, have been used to
study anti-tumor immunity in vivo. Cell lines that were derived
from spontaneous tumors can be manipulated in vitro to express
defined tumor antigens and re-introduced into a syngeneic host.
However, transplantable models have been criticized as they do
not resemble established spontaneous tumors (e.g., [42,43]). One
of the advances associated with pre-clinical drug discovery and
development has been the development of genetically engineered
mouse models (GEMM) for cancer that incorporate alterations in
known oncogenes and tumor suppressors. Breast cancer GEMMs
spontaneously develop lesions in mammary tissue that histologi-
cally resemble the human equivalent [44]. Yet GEMMs are not
without criticism, as Jacks and coworkers suggest that genetically
Figure 3. Gene expression clusters associated with invasive breast cancer exhibited differential cell-mediated immune response
relative to normal breast tissue. Relative immune cell infiltrate was estimated based upon the average expression of genes associated with NK
cells, T cells, and macrophages, as listed in Table 1 (A). Mean posterior probability associated with T helper cell and macrophage polarization in each
group (Group 1 - blue line, Group 2 - red line, Normal - black dotted line, random gene expression (null hypothesis) - gray shaded density distribution)
were estimated based upon mutually exclusive gene expression patterns that are associated with each cell subset, as also listed in Table 1 (B). WISP1
expression was increased in breast cancer relative to normal tissue samples and WISP1 expression correlated with GATA3 expression (C). The ratio of
IL12RB2 to IL12RB1 was increased in Group 2 patients relative to Group 1 patients and normal breast tissue samples (D). A 1:1 ratio between IL12RB2
and IL12RB1 gene expression is indicated by the gray dotted line in the scatter plot. In panels A, C, and D, bivariate scatter plots are shown below the
diagonal, marginalized histograms stratified by the three groups are shown on the diagonal, and correlation coefficients are shown above the
diagonal. Results are colored by group (Breast Cancer Group 1: blue, Breast Cancer Group 2: red, Normal breast tissue: black).
doi:10.1371/journal.pcbi.1003409.g003
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engineered mouse models of cancer may underestimate the
mutational and antigenic load of most human cancers [45]. Given
the observed immune gene expression signature observed in
human breast cancer tissue, we also wanted to determine whether
most common breast cancer GEMMs exhibit similar immune
gene signatures as the human disease.
Similar to the TCGA analysis presented in Figure 1, mRNA
expression results from 122 breast cancer tumor and normal breast
tissue samples obtained from a variety of genetically engineered
mouse models (GEMM) for breast cancer (see Figure 6 -
[GEO:GSE3165]) [46]. Within this GEMM data set, four gene
expression clusters were identified based upon a subset of genes
associated with anti-tumor immunity and immunosuppressive
mechanisms: a normal group and three breast cancer groups. In
contrast to the TCGA data, WISP1 was up-regulated in only a
small subset of 7,12-dimethylbenz[a]anthrazene (DMBA)-induced
breast cancer models. Moreover, the immune gene expression
signatures in the breast cancer GEMMs suggested that NK cell
infiltrate is unchanged, T cell infiltrate is suppressed, and that
macrophages are elevated relative to normal breast tissue (see
Figure 7A). This signature is different from the immune cell gene
signatures observed in the TCGA data set that suggest that NK
cells, T cells, and macrophages were either collective decreased in
group 1 or collectively increased in group 2 relative to normal
tissues. In terms of immune polarization, macrophages exhibit a
similar pattern in the GEMMs compared to the human samples,
where macrophages in normal tissue are skewed towards an M2
and macrophages in tumor tissue are skewed towards M1
phenotypes (see Figure 7B). In contrast, the inferred T cell
polarization states in GEMMs are different from human samples.
A regulatory T cell signature is highest in normal mammary tissue
and the different tumor models exhibit mixed immune polariza-
tion signatures that overlap with the null hypothesis signature. The
GEMM results also suggest that reduced T cell recruitment to
Figure 5. Basal copy numbers of IL12RB1, IL12RB2, and MHC class I in breast cancer cell lines were consistent with cohort group
assignment based upon molecular pathology. Copy numbers of membrane proteins IL12RB1 (A), IL12RB2 (B) and HLA-ABC (D) were quantified
using flow cytometry for four breast cell lines: 184A1 HMECs (blue), BT474 (HER2+/ER+/PR+) cells (red), SKBR3 (HER2+/ER2/PR2) cells (green), and
MDA-MD-231 (HER22/ER2/PR2) cells (black). Unstained cells are shaded in gray. Results are representative of three independent replicates. (C) The
ratio of IL12RB2/IL12RB1 was increased in MDA-MB-231 cells relative to the other three cell lines (* indicates a p-value,0.05, as estimated using an
unpaired two-tailed Student’s t-test).
doi:10.1371/journal.pcbi.1003409.g005
Figure 4. WISP1 and GATA3 gene expression correlate with protein expression. Representative deconvoluted color images derived from a
breast cancer tissue microarray probed using a WISP1 antibody and imaged using 3,39 diaminobenzidine and stained using hematoxylin for three
invasive breast cancer (A - top) and three normal breast (B - bottom) tissue samples (original tissue microarray images were obtained from www.
proteinatlas.org [64]). Deconvoluted intensity of WISP1 staining is shown in red while cellular structures stained using hematoxylin are shown in blue.
(C) The average intensity of WISP1 staining, as determined by color deconvolution of the RGB tissue microarray images, was increased in breast
carcinoma (** indicates a p-value,0.001, as estimated using an unpaired two-tailed Student’s t-test). Summary statistics are shown as mean +/2 SD.
The number of replicates included in the analysis is indicated by n. (D) GATA3 gene expression as quantified by Affymetrix microarray correlated with
GATA3 protein expression as quantified by reverse phase protein array. In panel D, a bivariate scatter plot for the 340 joint measurements is shown
below the diagonal, marginalized histograms stratified by the two breast cancer groups are shown on the diagonal, and a correlation coefficient is
shown above the diagonal.
doi:10.1371/journal.pcbi.1003409.g004
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Figure 6. Immune gene expression signatures in genetically engineered mouse models for breast cancer clusters into three groups.
mRNA expression obtained from normal and breast cancer carcinoma tissue samples derived from different genetically engineered mouse models
(columns) were hierarchically clustered into four groups based upon the log2 median normalized expression ratio for genes (rows) related to cell-
mediated cytotoxic immunity and tumor immunosuppression. The color-coded bar at the top of the heatmap indicates the four groups (Normals -
black, Group 1 - blue, Group 2 - red, and Group 3 - orange). Gene expression is shown as a row-normalized heatmap, where red denotes under-
expressed and violet denotes overexpressed relative to the population mean. Dendrogram indicates the degree of similarity among genes (rows) or
samples (columns) using the Ward’s minimum distance method in R.
doi:10.1371/journal.pcbi.1003409.g006
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mammary tumors in the GEMMs reduces the signal associated
with T cell polarization, which in turn makes identifying the T cell
polarization state from homogenized tissue samples difficult.
Similar discordance has been reported between human
inflammatory diseases and their corresponding mouse models
[47]. Collectively, the immune signatures in the set of GEMMs are
unlike that observed in the TCGA samples and motivate
developing pre-clinical mouse models that better reflect the
immune signature associated with invasive breast cancer in
humans. Given the discordance between GEMMs and humans,
the likelihood for a type 2 error in testing immunotherapies using
spontaneous mouse models for breast cancer seems high.
Unfortunately, developing GEMMs that better mimic human
anti-tumor immunity is a recommendation that has persisted for
over three decades [48]. In contrast to the 1980s, this work
illustrates how data obtained from large-scale studies, like the
Cancer Genome Atlas, coupled with in silico model-based inference
methods can be used to identify appropriate immune signatures.
These immune signatures can be used as design constraints in
genetically engineering better pre-clinical mouse models of cancer.
Discussion
In this retrospective study of the invasive breast cancer arm of
the Cancer Genome Atlas study, we made three main observa-
tions. First, type 1 cell-mediated cytotoxic immunity was
correlated with increased survival in patients with invasive TN
breast cancer and was predictor of survival independent of
molecular pathology. In the absence of a molecular targeted
therapy, an increase NK and T cell infiltrate and a shift from type
2 towards type 1 cell-mediated immunity correlated with a survival
advantage in patients with invasive TN breast cancer. These
correlates were also identified independent of tumor staging and
lymph node involvement. This observation is consistent with a
significant body of literature that correlate various molecular
characteristics of anti-tumor immunity with overall survival in
breast cancer, as reviewed by Andre et al. [49]. While many
studies focus on particular immune-related molecules, gene
expression profiling provides a less biased view of the immunologic
properties of anti-tumor immunity. As one of the most extensively
studied cancers, gene expression profiling of primary tumors (e.g.,
[50–54]) and tumor stroma [55] have identified immune classifiers
of clinical outcome in breast cancer. In contrast to a focus on
primary tumors, samples from age-matched normal breast tissue
were included in the analysis to gain insight into the immunologic
changes associated with oncogenic transformation, which led to
the second observation.
Second, oncogenic transformation in invasive breast cancer
was associated with an increase in WISP1 gene expression
(p{valuev1|10{15) and protein abundance (p{valuev
0:001). Prior studies of WISP1 in breast cancer have been mixed.
Xie and coworkers observed higher WISP1 gene expression in 20
of 44 breast cancer samples while the remaining samples exhibited
levels of expression similar to normal breast tissue [56]. In
contrast, Davies and coworkers found that WISP1 was reduced in
samples obtained from breast tumors compared to normal breast
tissue [57]. Here, the focus on invasive breast cancer and larger
sample size may explain some of the observed differences. WISP1
is a member of the family of connective tissue growth factors that is
induced by nuclear localization of beta-catenin [26] and partic-
ipates in stem cell differentiation and tumorigenesis [58]. While
the details remain to be fully elucidated, on-going work suggests
that proteolytic cleavage of E-cadherin enables membrane-bound
beta-catenin to localize to the nucleus and induce WISP1
expression [27]. In vivo, loss of E-cadherin plays an important
role in the metastatic potential of cancers [59]. While WISP1 has
been reported to influence neurodegeneration and osteogenesis
[60], a signaling mechanism has yet to be identified despite a
report suggesting that WISP1 binds the a5b1 integrin [61].
Third, the gene expression signature in invasive breast cancer
was consistent with WISP1 as a paracrine inhibitor of type 1 cell-
mediated immunity through inhibiting IL12 signaling and
promoting type 2 immunity. In particular, we found a highly
significant correlation between WISP1 and GATA3 (p{valuev
1|10{9) and a highly significant negative correlation between
WISP1 and PPARG (p{valuev1|10{15). While the increase in
Figure 7. Hierarchical clusters of GEMM gene expression exhibit different immune cell signatures. (A) Relative immune cell infiltrate was
estimated based upon the average expression of genes associated with NK cells (KLRD1, KLRC2, KLRC3), T cells (CD247, CD3G, CD3D, CD3E), and
macrophages (CD14, CPM, MRC1, ITGAM) in the breast cancer GEMM data set [46]. (B) Using model-based inference, the mean posterior probabilities
associated with T helper cell and macrophage polarization in each GEMM group were estimated based upon mutually exclusive gene expression
patterns that are associated with each cell polarization subset, as listed in Table 1. The immune polarization signature was compared to a signature
assembled from a bootstrapped ensemble of random sets of gene expression (i.e., a null hypothesis), as summarized by the gray shaded density
distribution. In both panels, results are colored by group indicated at the top of the GEMM heatmap shown in Figure 6 (Normals - black, Group 1 -
red, Group 2 - blue, and Group 3 - orange). In panel A, bivariate scatter plots are shown below the diagonal, marginalized histograms stratified by the
three groups are shown on the diagonal, and correlation coefficients are shown above the diagonal.
doi:10.1371/journal.pcbi.1003409.g007
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GATA3 is consistent with WISP1 as an inhibitor of IL12 signaling,
the negative correlation between WISP1 and PPARG was
unexpected and suggests that the reduction in PPARG may
relieve transcriptional repression of type 2 cytokine production by
T cells. Conventionally, exploratory data analysis is used to
identify genes or clusters of genes that correlate with clinical
outcome (e.g., [50–55]). To identify gene set classifiers, the gene
expression data set is subdivided into a training set - to discover
significant gene clusters - and a validation set - to confirm that the
gene cluster correlates with outcome. Here a more targeted
approach was used. Previously, we used a phenotypic assay that
incorporated in vitro, in silico, and unbiased proteomics methods to
discover a paracrine mechanism by which a mouse model for
melanoma regulates immune response to IL12 [27]. To validate
this mechanism, a retrospective analysis was used to identify
whether a gene expression signature that is consistent with WISP1
as a paracrine regulator of anti-tumor immunity exists in invasive
human breast cancer. This gene signature was embodied in PC2
and corresponded to oncogenic transformation. Inverse relation-
ships between type 1 cell-mediated cytotoxic immunity and
GATA3 and between IL12RB2 and GATA3 were also captured in
PC1 and PC3, respectively. Collectively, the first three PCs
captured 49% of the overall variance in gene expression.
The limitations of the analysis are such that the TCGA data
reflect homogenized tumor tissue and the genes that are associated
with the immune polarization signatures have pleiotropic biolog-
ical roles. For instance, GATA3 plays a role in both mammary
epithelial [62] and immune cell biology [63]. In terms of
mammary epithelial cell biology, GATA3 is thought to inhibit
breast cancer metastasis. GATA3 is up-regulated in luminal
epithelial cells and down-regulated in basal epithelial cells, which
have a higher propensity for invasion and metastasis. In this
TCGA study, mutations in GATA3 have a higher prevalence [14].
However, less than 2% of samples that exhibited basal-like and
HER2-enriched intrinsic subtype characteristics had mutations in
GATA3, specifically truncation mutations. TN breast cancer
samples were predominantly the basal-like subtype while
HER2+ samples corresponded to the HER2-enriched subtype.
In terms of immune cell biology, GATA3 promotes type 2 and
counter regulates type 1 T cell polarization, as captured in the
analysis by the negative loading coefficient for GATA3 in PC1 and
the reciprocal relationship between GATA3 and IL12RB2 in PC3.
Collectively, the data suggest that changes in GATA3 may reflect a
signature derived from immune cell biology rather than mammary
epithelial cell biology. We found that GATA3 expression was
correlated with WISP1 and that GATA3 was up-regulated in
invasive breast cancer compared to normal tissue. The increase
over normal in GATA3 was especially prevalent in patient samples
associated with the group 1 cohort, a cohort with reduced overall
survival for patients with TN breast cancer. In contrast, GATA3
expression was lower relative to normal tissue in a subset of the
group 2 cohort, a cohort with improved overall survival for
patients with TN breast cancer. Despite the increase in WISP1
associated with oncogenesis, the differences in immune bias
between the patient cohorts may reflect intrinsic differences in
sensitivity to local reprogramming of tumor-infiltrating lympho-
cytes. While this cross-sectional tumor biopsy study can not rule
out the possibility that the observed signatures are due to systemic
alterations in immune response, identifying local factors could help
improve the efficacy of many of the immunotherapies currently in
clinical trials, such as adoptive T cell transfer or immune
checkpoint inhibitors that increase systemic T cell numbers.
In summary, effective anti-tumor immunity is proportional to
the number and to the cytotoxic activity of immune cells that enter
the tumor microenvironment. Recent advances in cancer immu-
notherapy stem from increasing the number of tumor-infiltrating
immune cells by inhibiting immune checkpoints or adoptive T cell
therapy. Mirroring the clinical results of these therapies, we found
that a gene signature consistent with enhanced type 1 cell-
mediated cytotoxic immunity is a predictor of overall survival in
invasive breast cancer independent of molecular pathology. In
addition, this study also supports a link between epithelial-to-
mesenchymal transition - through secretion of WISP1 - and
repression of type 1 cell-mediated cytotoxic immunity - through
inhibition of IL12 signaling. From an evolutionary perspective, the
results also suggest that oncogenic transformation in invasive
breast cancer alters the selective fitness landscape through
reducing the efficacy of innate and adaptive immunity, which
function as important extracellular control mechanisms. Restoring
these extracellular control mechanisms will require a better
understanding of the dynamics associated with the shift in
polarization from type 1 to type 2 within tumor-infiltrating
lymphocytes and the sensitivity of this axis, in terms of both
quantity and quality, to pharmacological action. From a transla-
tional science perspective, these findings motivate a directed effort
to demonstrate - using pre-clinical mouse models of
invasive breast cancer that more accurately represent
the immune signature in human disease - that inhibiting
these paracrine immunosuppressive cues will improve the overall
response of current cancer immunotherapies. Moreover, model-
based inference helped identify the immune signatures that can be
used as design constraints in genetically engineering better pre-
clinical mouse models of cancer. This knowledge may be of
particular importance to patients with TN breast cancer, a patient
group that is underserved by the current generation of molecular
targeted therapies.
Materials and Methods
Breast tissue gene expression
Expression of genes associated with type 1 cell-mediated
immunity, as summarized in Table 1, in normal breast tissue
and invasive breast cancer were obtained from the breast cancer
arm of The Cancer Gene Atlas (TCGA) study [14]. In brief,
homogenized samples obtained from primary tumor (n = 520) and
matched normal breast tissue (n = 61) were obtained from patients
that were newly diagnosed with invasive breast adenocarcinoma
following surgical resection and that received no prior treatment
for their disease (chemotherapy or radiotherapy). Subsequent
treatments, clinical characteristics and biomarkers, and overall
outcome for all of the 520 tumor tissue samples and reverse-phase
protein array (RPPA) data for only 340 of the tumor tissue samples
were downloaded from the TCGA website (https://tcga-data.nci.
nih.gov/tcga/). The median age at diagnosis was 59 years of age
and the median follow-up time for overall survival was 22 months.
Tumor and normal breast tissue gene expression for this cohort
was obtained following array normalization by processing through
the Oncomine database (www.oncomine.org). In brief, Level 2
data obtained using Agilent mRNA expression microarrays were
downloaded from the TCGA website (https://tcga-data.nci.nih.
gov/tcga/) and the intensity of a given gene probe was normalized
to the median of the probe intensities across the entire array
sample. Expression of a given gene is expressed in terms of a log2
median-centered ratio, where genes that have a value less than
zero are expressed at a level less than the median and genes with a
value greater than zero are expressed at levels higher than the
median.
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Immunohistochemical analysis
The abundance of WISP1 in invasive breast cancer and normal
breast tissue was quantified by immunohistochemical analysis
using a tissue microarray derived from de-identified human breast
tissue samples, as provided by the Human Protein Atlas (www.
proteinatlas.org, Stockholm, Sweden [64]) and in accordance with
approval from the Uppsala University Hospital Ethics Committee.
The tissue microarray analysis included samples from 9 breast
adenocarcinomas (6 ductal and 3 lobular) and 3 normal breast
tissues from women that ranged in age from 23 to 87 years. The
tissue microarrays were processed as described by Uhlen et al. [65]
and probed using a rabbit polyclonal antibody against WISP1
(ab10737 - Abcam, Cambridge, MA) that was validated by
providing partly consistent staining patterns with another antibody
and gene/protein characterization data. WISP1 staining was
visualized using diaminogenzidine and microscopic tissue features
were visualized by counterstaining with Harris hematoxylin.
Immunohistochemically stained tissue microarrays were scanned
at 206 resolution (1 mm diameter) and provided as an 8-bit RGB
JPEG image. Pathological assessments of the images were
annotated manually. The average intensity of WISP1 staining
per tissue sample was quantified by deconvoluting the intensity of
WISP1 staining from nonspecific hematoxylin tissue staining in R
using the EBImage package and deconvolution approach described
by Ruifrok and Johnston [66].
Model-based inference and statistical analysis
Polarization of T helper cells and macrophages into different
subtypes are defined by differences in gene expression [29,31].
The genes associated with each subset are summarized in Table 1.
The log2 median-centered ratios of subset-defining genes were
normalized to the standard deviation of the observed values across
the entire cohort, that is a z-score. Immune cell polarization
among alternative subsets is assumed to be a mutually exclusive
process. Using Bayes theorem, the conditional probability that
cells contained within a homogenized tissue sample exhibit a
polarization bias, as represented by a model (Mi), given the
observed multi-gene expression signature, Y , can be express as:
P(Mi DY )~
P(Y DMi):P(Mi)Pn
i~1 P(Y DMi):P(Mi)
: ð1Þ
where P(Y DMi) is the likelihood of observing data Y given the
polarization model Mi, P(Mi) is the prior for the model, and n is
the number of polarization subsets. As we have equal ignorance a
priori as to how well the competing polarization models describe
the data, the priors for each model are set equal to 1=n. The
likelihood of observing increased expression of a defined multi-
gene signature (Mi) is the product of the likelihood of observing
increased expression of each gene (Vy : y[Mi) within the signature.
The likelihood can be defined using a simple Euclidian metric
based upon the z-score [67,68]:
P(Y DMi)~ P
Vy:y[Mi
1
(y{3)2
: P
Vy:y[Mi
1
(yz3)2
, ð2Þ
such that a higher z-score for genes (yj ) associated with a subset
(Mi) and a lower z-score for genes associated with a different
subset (Mi) corresponds to a higher likelihood. Bootstrap
resampling is an effective computational method for estimating
the uncertainty associated with a calculated value [69]. Bootstrap
resampling with replacement (nBootstrap =1000) from the set of all
observed gene expression values was used to establish a predicted
polarization bias for an equivalent size patient cohort
(nPatients =200) that is consistent with a null hypothesis, that is
the gene expression values are random samples and contain no
information regarding immune cell polarization. The distribution
in posterior probability of immune bias for a given cohort was
obtained using kernel density estimation. Statistical significance
associated with the mean posterior probability of immune bias for
a given cohort was compared to the null hypothesis. A p-value
corresponds to the likelihood that the observed posterior
probability (or a more extreme value) of immune bias for a cohort
is due to random chance. A p-value,0.05 was considered
significant.
The variation and correlation among the gene expression
measurements were characterized using principal component
analysis (PCA), which is described in more detail in the
Supplemental Text S1. The scoring coefficients for each of the
top 10 principal components are listed in Dataset S1. Statistical
differences between means were assessed using unpaired Student’s
t-tests. All Student’s t-tests were two-sided. Statistical significance
associated with a correlation between gene expression values
within a sample was assessed using a Pearson product-moment
correlation coefficient. A one-sided test of the Pearson’s correlation
coefficient was used to determine whether a correlation coefficient
was positive or negative. A p-value,0.05 was considered
significant. Overall survival time was used as a clinical outcome
metric. To estimate cumulative survival probability, Kaplan-Meier
survival curves were estimated from the cohort overall survival
data. Statistical significance associated with a difference in survival
between two groups was estimated using the Peto & Peto
modification of the Gehan-Wilcoxon test and the Cox propor-
tional hazards regression model, as implemented in the R survival
package. Based upon criticism of other gene signatures associated
with cancer survival [70], the significance of the hazard ratio
associated with a type 1 immune polarization bias was estimated
by comparing the hazard ratio predicted by type 1 immune
polarization model against a distribution in hazard ratios predicted
from an ensemble of random models that were created by
bootstrap resampling (nBootstrap =1000). Each random model was
created by randomly assigning a small subset of genes selected
from the genes shown in Table 1 to one of four polarization states.
The number of genes associated with each of the four polarization
states was the same as listed in Table 1. A p-value corresponds to
the likelihood that the observed hazard ratio (or a more extreme
value) associated with type 1 immune polarization is due to
random chance, where a p-value,0.05 was considered significant.
All analyses were performed using R software version 2.14.1
(http://www.r-project.org). Overall, the study was performed in
concordance with the REMARK guidelines [71].
Cell lines, antibodies, and reagents
The nontumorigenic human breast epithelial cell line 184A1
was obtained from ATCC (Manassas, VA), the human HER2+
breast cancer cell lines (BT474 and SKBR3) were kindly provided
by Dr. Jia Luo (University of Kentucky; Lexington, KY), and a cell
model of triple negative breast cancer (MDA-MB-231) was a gift
from Dr. J. M. Ruppert (West Virginia University). The 184A1,
BT474, and SKBR3 cell cultures were maintained at 37oC in 5%
CO2 in media supplemented as described previously [72].
Similarly, the MDA-MB-231 cell line was maintained in
Dulbecco’s Modification of Eagle’s Medium (DMEM) supple-
mented with 10% (v/v) heat inactivated fetal bovine serum (FBS)
(Hyclone, Inc., Logan, UT), L-glutamine, and penicillin/strepto-
mycin (BioWhittaker, Walkersville, MD). Allophycocyanin (APC)-
conjugated mouse anti-human CD212 (IL12Rb1 - Clone 2.4E6)
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and APC-conjugated mouse anti-human HLA-A,B,C (Clone G46-
2.6) were purchased from BD Biosciences (San Diego, CA,
U.S.A.). Phycoerythrin (PE)-conjugated mouse anti-human IL-12
receptor b2 (IL12Rb2 - Clone 305719) was purchased from RnD
Systems (Minneapolis, MN). ChromPure human IgG (whole
molecule) were purchased from Jackson Immuno Research (West
Grove, PA, U.S.A.). Quantum Simply Cellular uniform micro-
spheres conjugated to anti-mouse IgG were purchased from Bangs
Laboratories (Fishers, IN).
Quantification of protein copy number
Fluorescence-activated cytometry was performed as described
[27,38]. Quantum Simply Cellular calibration beads that contain
four Quantum Simply Cellular microsphere populations with
different mouse IgG antibody binding capacities were stained with
fluorophore-conjugated monoclonal antibodies specific for
IL12Rb1, IL12Rb2, or HLA-ABC. The cells were analyzed using
a FACSAria flow cytometer and FACSDiva Version 6.1.1
software (BD Biosciences). No stain controls were used as negative
flow cytometry controls. Single stain controls were used to
establish fluorescent compensation parameters. Cellular events
were identified by forward and side scatter characteristics. On
average, 2|104 events were analyzed. Flow cytometry data was
exported as FCS3.0 files and analyzed using R/Bioconductor [73].
Supporting Information
Dataset S1 Data.xls. This Microsoft Excel file contains gene
expression values used and scoring coefficients for each of the top
10 principal components.
(XLS)
Figure S1 Tumor characteristics associated with hier-
archical clustering of patients. Molecular pathology (top),
PAM50 intrinsic tumor subtypes, posterior estimation of immune
cell bias, and immune cell recruitment signature aligned to
hierarchical clustering of the gene expression profiles. The
molecular pathology (Normal, Ductal, Lobular, Other, ER+,
PR+, HER2+) and PAM50 intrinsic tumor subtypes (Basal,
HER2-like, Luminal A, Luminal B, Normal-like) are indicated
by a blue vertical bar. Posterior estimation of immune cells bias is
indicated by black-white shaded bar (p(:) = 0: black, p(:) = 1: white).
The magnitude of the immune cell recruitment signature
(Macrophages (MW), T cells, and NK cells) is indicated by a
ROYGBIV color scheme, where red indicates a low average log2
median-centered value and violet indicates a high average log2
median-centered value. Dendrogram indicates the degree of
similarity in gene expression among samples (columns) using the
Wards minimum distance method in R. Dendrogram was
calculated based on gene expression shown in Figure 1.
(TIFF)
Figure S2 Principal component analysis of gene expres-
sion values projected onto patient cohorts. (A) Column
dendrogram was calculated based on gene expression shown in
Figure 1. Subtypes of invasive breast cancer cohort are indicated
by color bars: group 1a - black (Normal), group 1b - blue, group 1c
- green, and group 2 - red. (B) Variance captured by principal
components, expressed as a percentage. (C) Within the entire
population, the density distributions of subtypes, stratified by
molecular pathology, marginalized along PC1 are shown for triple
negative (TN - gray), HER2+ (yellow), and other subtypes (blue).
Below the density distributions, the projection of invasive breast
cancer cohort along PC1 and PC2 dimensions. Points are color
coded as shown in panel A. Triple negative breast cancer samples
in groups 1b, 1c, and 2 are filled circles. Samples derived from
normal breast tissue are filled black.
(TIF)
Figure S3 External validation of TCGA gene expression
signature. Projections along the first four principal component
directions of the invasive breast cancer samples (A) and normal
breast tissue samples (B) reported in four potential validation
studies (black - TCGA [14], orange - Karnoub et al. [76], blue -
Finak et al. [55], and red - Gluck et al. [34]). In panel B, the
colored contour lines indicate the PC values that enclose 95% of
the invasive breast cancer samples. Contours were estimated from
the data shown in panel A by kernel density estimation. (C and D)
Biplot projections of the genes along the first two principal
component directions (panel C - Gluck et al. [34], panel D -
TCGA [14]). Synthetic samples were generated by random
bootstrap resampling with replacement of the set of all gene
expression values reported for a study. The colored ovals indicate
different noise thresholds by enclosing different fractions of the
biplot projections of the synthetic samples (median +/21 s.d. (red),
+/22 s.d. (yellow), +/23 s.d. (green), +/25 s.d. (blue), and +/27
s.d. (violet)). (E) A biplot comparison of the covariation observed in
gene expression in the Gluck study [34](blue circles) to the TCGA
study [14](red circles). Projections for the same gene observed in
the two different studies are connected by a line. The top 10 genes
that exhibited the greatest differences between studies are
highlighted in bold.
(TIF)
Figure S4 Comparisons of gene expression using pair-
wise scatter plots. (A) Genes in PC2 with high loading
coefficients: WISP1, GATA3, PPARG, and IL6. (B) Comparison
among GATA3 gene expression, copy number, and protein
expression. Bivariate scatter plots of log2 median-centered ratios of
gene expression (GATA3), of copy number (cnGATA3), and of
protein abundance (peGATA3) as measured by reverse phase
protein array. (C) Comparison among GATA3, IL12RB1, and
IL12RB2 gene expression. In all panels, the scatter plots are shown
below the diagonal, marginalized histograms stratified by the two
invasive breast cancer groups are shown on the diagonal, and
Pearson covariation coefficients are shown above the diagonal.
Results are colored by group (Breast Cancer Group 1: blue, Breast
Cancer Group 2: red). All values were obtained from the TCGA
website (https://tcga-data.nci.nih.gov/tcga/).
(TIF)
Figure S5 Pairwise scatter plots for genes previously
associated with tumor immunosuppression. Genes shown
include FOXP3, RORC, GATA3, HMGB1 [77], TGFB1, PDCD1
[78–80], CD274 [78–80], IL10, IDO1, ARG1, HIF1A [81], BTLA,
HAVCR2 (TIM-3), LAG3, MICA/MICB, and VTCN1(B7-H4) [82].
Bivariate scatter plots of log2 median-centered ratios of gene
expression are shown below the diagonal, marginalized histograms
stratified by the three groups are shown on the diagonal, and
correlation coefficients are shown above the diagonal. Results are
colored by group (Breast Cancer Group 1: blue, Breast Cancer
Group 2: red, Normal breast tissue: black).
(TIFF)
Figure S6 Posterior estimation of immune bias using
revised T helper cell polarization signatures. Mean
posterior probability associated with T helper cell and macro-
phage polarization in each group (Group 1 - blue, Group 2 - red,
Normal - green) were estimated based upon a revised mutually
exclusive gene expression signature that are associated with each
WISP1 Inversely Correlates with Type 1 Immunity
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cell subset, as discussed in the main text. The mean values in
posterior distributions of the null hypothesis in immune bias were
estimated for each of the 1000 bootstrap resamples and shown as a
distribution (gray shaded density distribution).
(TIFF)
Figure S7 Model-based inference of type 1 immune
polarization is a better predictor of improved outcome
than a random model of identical size. The x-axis denotes
the hazard ratio of the clinical outcome associated with either a
model representing type 1 T cell polarization (red squares) or a
random model assembled from a random sample of the genes
listed in Table 1 (box and whisker plot) obtained using a Cox
proportional hazards model for the indicated time frames (1 Year,
3 Years, 5 Years, and 6 Years). The distribution in hazard ratio
associated with the random model was assembled from 1000
bootstrapped replicates (box and whisker plot), where the median
is represented by the vertical bar, the first through the third
quartile is indicated by the box, and the whiskers indicate 62.7
standard deviations. Outliers are indicated by the circles and
suggest that the distribution in hazard ratios are skewed towards
lower hazard ratios. This is not surprising as the genes listed in
Table 1 are resampled but genes involved in anti-tumor immunity
are overrepresented. An important point here is that we are not
regressing a random immune signature to clinical outcome within
essentially the same data set but used an immune signature derived
from independent studies that has strong mechanistic interpreta-
tion. Given the extensive literature describing gene signatures
associated with T cell polarization, the signature has a low a priori
likelihood for a Type 1 error, although for this bootstrap example
we assume equal a priori likelihood for this signature as a random
model. As suggested by the skewed tail, one could identify a better
signature based upon correlation between clinical outcome and a
model created from some permutation of the genes in Table 1.
However from a mechanistic perspective, this could be interpreted
as overfitting the data.
(TIF)
Table S1 Results for Cox proportional hazards regres-
sion model. The Cox model: (Survival,p(Th1 T cell)+Mole-
cular Pathology). The results suggest that the posterior estimate of
a Th1 immune cell polarization gene expression signature (i.e.,
p(Th1 T cell)) is a predictor of overall survival independent of the
molecular pathology. We also found that the other T helper cell
polarization states (i.e., p(Th2 T cell), p(Th17 T cell), and p(iTreg
T cell)) were not predictive.
(PDF)
Text S1 TextS1.pdf. This PDF file contains: 1. Principal
component analysis 2. External validation of the TCGA gene
expression signature References.
(PDF)
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